Compare · CRL vs IQV
CRL vs IQV
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $34.69B, about 3.1x CRL ($11.14B).
- Over the past year, CRL is up 49.8% and IQV is up 31.8% - CRL leads by 18.0 points.
- CRL has been more active in the news (2 items in the past 4 weeks vs 1 for IQV).
- Both have 25 recent analyst ratings on file.
- Company
- Charles River Laboratories International Inc.
- IQVIA Holdings Inc.
- Price
- $231.30+0.67%
- $207.86+0.16%
- Market cap
- $11.14B
- $34.69B
- 1M return
- +23.25%
- +14.92%
- 1Y return
- +49.83%
- +31.82%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NYSE
- IPO
- 2000
- 2013
- News (4w)
- 2
- 1
- Recent ratings
- 25
- 25
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest CRL
- Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Director Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Charles River upgraded by Morgan Stanley with a new price target
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
- EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)
- EVP, Chief Information Officer Mintz Mark was granted 2,534 shares and covered exercise/tax liability with 369 shares, increasing direct ownership by 29% to 9,546 units (SEC Form 4)
Latest IQV
- IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
- IQVIA downgraded by Morgan Stanley with a new price target
- Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities